Table 1 Demographic and clinical characteristics
From: Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study
Gender | Age at natalizumab start | Relapses in the year before natalizumab | N° of natalizumab infusions | EDSS after last natalizumab infusion | Brain MRI at 6 months after rituximab | Brain MRI at 12 months after rituximab |
|---|---|---|---|---|---|---|
F | 29 | 2 | 35 | 1.5 | unchanged | unchanged |
F | 44 | 2 | 76 | 3.5 | unchanged | unchanged |
F | 32 | 1 | 27 | 2.0 | unchanged | unchanged |
F | 38 | 2 | 69 | 2.0 | unchanged | unchanged |
M | 25 | 1 | 37 | 4.5 | unchanged | unchanged |
F | 33 | 2 | 39 | 3.5 | unchanged | unchanged |
F | 40 | 1 | 22 | 2.0 | unchanged | unchanged |
F | 30 | 2 | 67 | 3.5 | unchanged | n.a. |
F | 35 | 2 | 71 | 2.0 | unchanged | n.a. |
M | 32 | 2 | 30 | 7.0 | unchanged | unchanged |